Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Soligenix Inc SNGX shares surged 221.5% on heavy volume of 23.6 million shares. Interim update on the study evaluating extended Hybryte treatment for early-stage CTCL. Positive responses to HyBryte therapy seen in patients, with promising safety profile. HyBryte treatment resulted in 60% of patients achieving a 50% or better improvement. Soligenix anticipates completing the study and participating in a confirmatory Phase 3 trial.
- Soligenix Inc SNGX shares surged 221.5% on heavy volume of 23.6 million shares.
- Interim update on the study evaluating extended Hybryte treatment for early-stage CTCL.
- Positive responses to HyBryte therapy seen in patients, with promising safety profile.
- HyBryte treatment resulted in 60% of patients achieving a 50% or better improvement.
- Soligenix anticipates completing the study and participating in a confirmatory Phase 3 trial.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.